Results of a clinical trial of an EGFR-agent called osimertinib was recently published in the New England Journal of Medicine. A short video was made to discuss this important trial. Based on the results, it is expected that the FDA will approve osimertinib as first-line treatment for patients with EGFR-mutated lung cancer. The drug is already approved (brand name Tagrisso) for patients whose lung cancer has the T790M mutation. nejm.org/do/10.1056/NEJMdo0...
Video about a lung cancer clinical tri... - Lung Cancer Support
Video about a lung cancer clinical trial by the New England Journal of Medicine
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
The FDA based their approval on the results of the clinical trial ADAURA which showed that patients...
EGFR mutations on exon 20 and exon 21
stage 4 lung cancer.
My PD-L1 is between 30 and 40%, and I have EGFR S768I (exon 20) and EGFR...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
or ALK. The FDA based their approval on the results of the clinical trial IMpower-110 which showed...
About stages of lung cancer
Large pleural based parenchymal mass measuring about 43*68 mm seen in the right lung base in...
Farewell to our dear friend Anita
force that put the EGFR Resisters into a partnership with the (then) Addario Lung Cancer...
NED means I should feel happy, right?
Has anyone received the Covid-19 Vaccine while taking Immunotherapy?
Devastated! my Non-Small Cell Lung Cancer Transformed into Small Cell Lung Cancer
Cuban vaccination to cure lung cancer
Liver cancer and now suspected lung cancer 
